Usefulness of F-18 FDG PET/CT in the Evaluation of Early Treatment Response After Interventional Therapy for Hepatocellular Carcinoma

Nuclear Medicine and Molecular Imaging

Volumn 46, Issue 2, 2012, Pages 102-110

  Kim, Sung Hoon ^a   Won, Kyoung Sook ^a   Choi, Byung Wook ^a   Jo, Il ^a   Zeon, Seok Kil ^a   Chung, Woo Jin ^a   Kwon, Jung Hyeok ^a  

^a Keimyung University   (South Korea)

Author keywords

F 18 FDG; Hepatocellular carcinoma; Interventional therapy; Locoregional therapy; PET CT; Response

Indexed keywords

ALPHA FETOPROTEIN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84861614992     PISSN: 18693474     EISSN: 18693482     Source Type: Journal    
DOI: 10.1007/s13139-012-0138-8     Document Type: Article

References (37)

1. Röcken C, Carl-McGrath S. Pathology and pathogenesis of hepatocellular carcinoma. Dig Dis. 2001; 19: 269-78.
2. Higashi T, Hatano E, Ikai I, Nishii R, Nakamoto Y, Ishizu K, et al. FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2010; 37: 468-82.
3. Poon RT, Fan ST, Tsang FH, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg. 2002; 235: 466-86.
4. Thabet A, Kalva S, Gervais DA. Percutaneous image-guided therapy of intra-abdominal malignancy: imaging evaluation of treatment response. Abdom Imaging. 2009; 34: 593-609.
5. Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. Current management strategy of hepatocellular carcinoma. World J Gastroenterol. 2009; 15: 3210-6.
6. Kwon JH. Is percutaneous ethanol injection therapy still effective for hepatocellular carcinoma in the era of radiofrequency ablation? Gut Liver. 2010; 4: S105-12.
7. Livraghi T. Radiofrequency ablation, PEIT, and TACE for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2003; 10: 67-76.
8. Lim HK, Han JK. Hepatocellular carcinoma: evaluation of therapeutic response to interventional procedures. Abdom Imaging. 2002; 27: 168-79.
9. Kim KW, Lee JM, Choi BI. Assessment of the treatment response of HCC. Abdom Imaging. 2011; 36: 300-14.
10. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30: 52-60.
11. 18F-FDG PET/CT. J Nucl Med. 2010; 51: 1849-56.
12. 18F-FDG PET after radiofrequency ablation therapy. Oncol Rep. 2007; 18: 1469-73.
13. 18F-FDG positron tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients. Liver Transpl. 2010; 16: 767-72.
14. Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol. 1999; 94: 3314-9.
15. Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol. 2000; 32: 792-7.
16. Sun L, Wu H, Guan YS. Positron emission tomography/computer tomography: challenge to conventional imaging modalities in evaluating primary and metastatic liver malignancies. World J Gastroenterol. 2007; 13: 2775-83.
17. 18F-FDG PET/CT. World J Hepatol. 2009; 31: 90-7.
18. Torizuka T, Tamaki N, Inokuma T, Magata Y, Yonekura Y, Tanaka A, et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med. 1994; 35: 1965-9.
19. Kim JW. Diagnosis of hepatocellular carcinoma. J Kor Liver Cancer Study Group. 2010; 10: 1-5.
20. Lammertsma AA, Hoekstra CJ, Giaccone G, Hoekstra OS. How should we analyse FDG PET studies for monitoring tumour response? Eur J Nucl Med Mol Imaging. 2006; 33: S16-21.
21. Seo S, Hatano E, Higashi T, Hara T, Tada M, Tamaki N, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res. 2007; 13: 427-33.
22. Imperiale A, Federici L, Lefebvre N, Braun JJ, Pfumio F, Kessler R, et al. F-18 FDG PET/CT as a valuable imaging tool for assessing treatment efficacy in inflammatory and infectious diseases. Clin Nucl Med. 2010; 35: 86-90.
23. Veit P, Antoch G, Stergar H, Bockisch A, Forsting M, Kuehl H. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur Radiol. 2006; 16: 80-7.
24. Purandare NC, Rangarajan V, Shah SA, Sharma AR, Kulkarni SS, Kulkarni AV, et al. Therapeutic response to radiofrequency ablation of neoplastic lesions: FDG PET/CT findings. Radiographics. 2011; 31: 201-13.
25. Becker CD, Grossholz M, Mentha G, Roth A, Giostra E, Schneider PA, et al. Ablation of hepatocellular carcinoma by percutaneous ethanol injection: imaging findings. Cardiovasc Intervent Radiol. 1997; 20: 204-10.
26. Jiang B, Lou Q, Ding XF, Sa XY, Chen LR, Yu SY, et al. Histopathological changes in rat transplanted hepatoma after lipiodol transarterial embolization. Zhonghua Zhong Liu Za Zhi. 2004; 26: 205-8.
27. 18FDG-PET/CT. Ai Zheng. 2005; 24: 1118-23.
28. Lokken RP, Gervais DA, Arellano RS, Tuncali K, Morrison PR, Tatli S, et al. Inflammatory nodules mimic applicator track seeding after percutaneous ablation of renal tumors. AJR Am J Roentgenol. 2007; 189: 845-8.
29. 18F-FDG PET to evaluate the effectiveness of radiofrequency ablation of liver metastases. AMJ Am J Roentgenol. 2007; 189: 1199-202.
30. Heusner TA, Fronz U, Jentzen W, Verhagen R, Forsting M, Bockisch A, et al. The effect of different chemoembolization materials on CT-based attenuation correction in PET/CT. Rofo. 2007; 179: 1159-65.
31. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999; 19: 61-77.
32. Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem. 2010; 56: e1-48.
33. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol. 2001; 35: 421-30.
34. Benson 3rd AB, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009; 7: 350-91.
35. Giovannini M, Elias D, Monges G, Raoul JL, Rougier P. Hepatocellular carcinoma. Br J Cancer. 2001; 84: 74-7.
36. Leung TWT, Patt YZ, Lau WY, Ho SKW, Yu SCH, Chan ATC, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res. 1999; 5: 1676-81.
37. Lee JK, Chung YH, Song BC, Shin JW, Choi WB, Yang SH, et al. Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization. J Gastroenterol Hepatol. 2002; 17: 52-8.